BIO-TECHNE Corp Available-for-sale Securities, Amortized Cost Basis
BIO-TECHNE Corp (TECH) had Available-for-sale Securities, Amortized Cost Basis of $29.50 million as of 2016-03-31, per its 10-Q filed 2016-05-10.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2016-05-10
- 2016-03-31: Available-for-sale Securities, Amortized Cost Basis $29.50M.
- 2015-12-31: Available-for-sale Securities, Amortized Cost Basis $29.50M.
- 2015-09-30: Available-for-sale Securities, Amortized Cost Basis $29.50M.
- 2015-06-30: Available-for-sale Securities, Amortized Cost Basis $33.60M.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2016-03-31 | $29.50M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $29.50M 10-Q · filed 2016-02-09 | |
| 2015-09-30 | $29.50M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $33.60M 10-Q · filed 2016-05-10 | |
| 2015-03-31 | $35.00M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $37.20M 10-Q · filed 2015-02-09 | |
| 2014-09-30 | $37.10M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $40.70M 10-Q · filed 2015-05-11 | $40.74M 10-K · filed 2014-08-29 |
| 2014-03-31 | $235.00M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $243.00M 10-Q · filed 2014-02-04 | |
| 2013-09-30 | $233.00M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $241.03M 10-K · filed 2014-08-29 | |
| 2013-03-31 | $239.00M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $231.00M 10-Q · filed 2013-02-11 | |
| 2012-06-30 | $229.97M 10-K · filed 2013-08-29 | |
| 2011-06-30 | $194.17M 10-K · filed 2012-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |